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A Clinical Prognostic Index for Patients Treated with
Erlotinib in National Cancer Institute of Canada Clinical
Trials Group Study BR.21
Marie Florescu, MD, FRCPC,* Baktiar Hasan, PhD,† Lesley Seymour, MD,† Keyue Ding, PhD,†
and Frances A. Shepherd, MD, FRCPC*
Introduction: BR.21 demonstrated significant survival benefit for
non-small cell lung cancer patients receiving erlotinib compared
with placebo. We undertook to characterize, by exploratory subset
analysis, patients less likely to benefit from erlotinib.
Methods: Using stratification and potential prognostic factors, Cox
regression with stepwise selection with minimum Akaike Informa-
tion Criteria was used to separate erlotinib patients into risk cate-
gories based on 10th, 50th, and 90th percentiles of prognostic index
scores. The hypothesis was that characteristics of treated patients in
the highest risk group would be predictive of lack of benefit from
erlotinib when comparing erlotinib to placebo patients in the same
risk group.
Results: Ten factors (smoking history, performance status, weight
loss, anemia, lactic dehydrogenase, response to prior chemotherapy,
time from diagnosis, number of prior regimens, epidermal growth
factor receptor copy, and ethnicity) were predictive of overall
survival for erlotinib-treated patients and were used in the final
model. Four risk groups were derived from the index score of the
Prognostic Model: Low Risk (HR  0.34, p  0.001), Intermediate
Low and Intermediate High Risk (HR 0.76, p  0.05; HR 0.92; p 
0.51) and High Risk (HR 1.07; p  0.78). Median survivals for
erlotinib (placebo) patients in each group were 20.6 (8.9), 10.4 (7.6),
4.0 (4.1), 1.9 (2.3) months. The trend test showed that higher risk
was associated with shorter survival (p  0.001) and less treatment
effect (p  0.03).
Conclusions: By establishing a prognostic model, we identified a
small group of patients who did not seem to benefit from erlotinib in
this study. This model requires prospective validation to confirm that
it is both prognostic and predictive of outcome.
Key Words: Erlotinib, Non-small cell lung cancer, EGFR inhibitor,
Prognostic.
(J Thorac Oncol. 2008;3: 590–598)
Lung cancer is now an epidemic of global proportion. Itcauses 1 million deaths per year worldwide1 and is the
number one cause of death due to cancer in the Western
World.1,2 For patients with advanced metastatic non-small cell
lung cancer (NSCLC), conventional chemotherapy offers im-
provement in symptoms and modest prolongation of survival.3
However, even the most active chemotherapeutic regimens in-
duce clinical response in only 30 to 40% of patients, and survival
is prolonged, on average, by only a few months.3–5
Several cooperative groups have examined their data-
bases to determine prognostic factors for patients receiving
systemic chemotherapy to identify the most suitable patients for
treatment.6–11 The most important adverse clinical factors re-
ported from several studies of chemotherapy for patients with
advanced NSCLC include higher stage, poor performance status
(PS 2–3), male sex, age over 70, presence of multiple metastases
or liver metastases, and a history of weight loss. Hematologic
and biochemical markers predictive of poor survival include
elevated serum levels of lactic dehydrogenase (LDH), calcium,
CA19.9, CA125, and anemia.7–11 In general, these analyses
included only patients receiving first-line chemotherapy and
similar analyses of prognostic factors for patients receiving
second or even third-line therapies have not yet been per-
formed.11 Such analyses may be of particular importance in
patients for whom third-line treatment is being considered in
view of the extremely low response rates and brief survival that
have been reported for chemotherapy.11
The new oral tyrosine kinase inhibitors of the epidermal
growth factor receptor (EGFR) erlotinib and gefitinib have
been shown to induce response, improve symptoms and in
some instances prolong survival in previously treated patients
with NSCLC.12,13 The National Cancer Institute of Canada
Clinical Trials Group (NCIC CTG) BR.21 study compared
erlotinib to placebo following first-line or second-line chemo-
therapy in patients with advanced NSCLC.14 Despite an overall
response rate of only 9%, treatment with erlotinib was associated
with significant improvements in survival (HR  0.70, p 
0.001), progression-free survival, quality of life and in lung
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TABLE 1. Analysis of Disease Status at 8 Weeks
Factor
Number
Evaluable
Early PD Within
First 8 wk
Disease Control
(CR/PR/SD) p
Treatment 0.0001
Erlotinib 398 211 (53.0%) 187 (47.0%)
Placebo 205 147 (71.7%) 58 (28.3%)
Age 0.310
60 yr 166 93 (56.3%) 73 (44.0%)
60 yr 232 118 (51.0%) 114 (49.0%)
Gender 0.698
Male 260 136 (52.3%) 124 (47.7%)
Female 138 75 (54.4%) 63 (45.6%)
Pathology 0.526
Adenocarcinoma 196 107 (54.6%) 89 (45.4%)
Squamous 121 59 (48.8%) 62 (51.2%)
Other 81 45 (55.6%) 36 (44.4%)
Performance status 0.007
0, 1 258 124 (48.1%) 134 (51.9%)
2, 3 140 87 (62.1%) 53 (37.9%)
Response to prior
treatment
0.006
CR  PR 162 76 (46.9%) 86 (53.1%)
PD 82 56 (68.3%) 26 (31.7%)
SD 154 79 (51.3%) 75 (48.7%)
Prior regimens 0.846
1 200 107 (53.5%) 93 (46.5%)
2, 3 198 104 (52.5%) 94 (47.5%)
Prior platinum 0.283
Yes 371 194 (52.3%) 177 (47.7%)
No 27 17 (63.0%) 10 (37.0%)
Smoking history 0.255
Current 220 121 (55.0%) 99 (45.0%)
Ever 64 37 (57.8%) 27 (42.2%)
Never 93 41 (44.1%) 52 (55.9%)
Unknown 21 12 (57.1%) 9 (42.9%)
Ethnicity 0.024
Oriental 52 20 (38.5%) 32 (61.5%)
Other 346 191 (55.2%) 155 (44.8%)
Time from diagnosis 0.053
12 mo 180 105 (58.3%) 75 (41.7%)
12 mo 218 106 (48.6%) 112 (51.4%)
Weight loss 0.0007
5% 254 117 (46.1%) 137 (53.9%)
5% 129 86 (67.7%) 43 (33.3%)
Unknown 15 8 (53.3%) 7 (46.7%)
LDH 0.279
Normal 195 96 (49.2%) 99 (50.8%)
Increased 184 103 (56.0%) 81 (44.0%)
Unknown 19 12 (63.2%) 7 (36.8%)
Anemia 0.008
Yes 281 161 (57.3%) 120 (42.7%)
No 117 50 (42.7%) 67 (57.3%)
EGFR protein
expression
0.006
Positive 96 39 (40.6%) 57 (59.4%)
Negative 74 48 (64.9%) 26 (35.1%)
Unknown 228 124 (54.4%) 104 (45.6%)
(Continued )
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cancer-related symptoms. The Iressa Survival Evaluation in
Lung Cancer study15 was similar in design to BR.21 and com-
pared gefitinib to placebo in patients who were either refractory
to or intolerant of first-line or second-line chemotherapy. Overall
survival was not prolonged significantly in the entire study
population, although certain subgroups including Asian patients
and lifetime nonsmokers appeared to derive benefit.
In both BR.21 and Iressa Survival Evaluation in Lung
Cancer, certain clinical and laboratory factors including female
sex, Asian ethnicity, adenocarcinoma histology, a history of
never having smoked, the presence of EGFR mutations, high
gene copy number and EGFR protein expression were predictive
of higher response rates, although in BR.21, with the exception
of smoking history, these factors did not predict for a differential
effect of erlotinib treatment on survival.16
Factors predictive of lack of response or short survival
in response to treatment with EGFR inhibitors have not been
assessed. In view of the low response rates seen in the second
and third-line setting, we felt that it might be of importance to
identify patients who might be less likely to benefit from this
form of therapy. We postulated that patients who progressed
within 8 weeks of initiating therapy (i.e., before or at the time
of the first assessment of response) or those who died within
3 months of initiating study treatment might demonstrate
baseline clinical and laboratory characteristics that could
differentiate them from responding patients. We also hypoth-
esized that the characteristics of the treated patients who had
the shortest survival would also be predictive of lack of
survival benefit from erlotinib when erlotinib and placebo
patients in the same risk group were compared. We report
here the results of our analyses of early progression and early
death, and present a prognostic model derived from patients
treated in the NCIC CTG BR.21 trial.
METHODS
Patients
The NCIC CTG BR.21 study has been described pre-
viously.14 Briefly, 731 patients with incurable Stage IIIB/IV
NSCLC after failure of at least one, but no more than two
prior chemotherapeutic regimens for advanced or metastatic
disease were randomized 2:1 to receive 150 mg daily of
erlotinib or placebo after stratification by center, PS, best
response to prior therapy, number of prior regimens, and
exposure to prior platinum. The primary end point of the
study was overall survival. A total of 731 patients entered the
study and 587 (80%) had died at the time of database lock.
The present analysis was based on all treated (erlotinib or
placebo) patients. Four untreated randomized patients (three
in the erlotinib arm and one in the placebo arm) were
removed leaving 727 patients available for the analyses.
Statistical Analysis
The Prognostic Index17–19 was built first in the treat-
ment arm, using stratification factors and potential prognostic
factors from BR.21. The Cox regression model20 with step-
wise selection procedures by minimum AIC18 was used to
establish a prognostic model for erlotinib-treated patients
first. Ten variables that gave a minimum AIC to the Cox
model were used in the final model. Then, based on these
variables, a prognostic scoring system17,18 was developed that
could be applied in the clinical setting to separate erlotinib-
treated patients into four risk groups based on the 10th, 50th,
and 90th percentiles of the score. The same risk criteria were
also applied subsequently to the placebo arm.21 Our hypoth-
esis was that the characteristics that determined the highest
risk group of the treated patients (highest point score and
poorest survival) would also be predictive of lack of benefit
from erlotinib when compared with placebo patients in the
same risk group based on the same criteria. We also hypoth-
esized that the degree of survival benefit would vary among
the four risk groups.
For the 603 patients in whom early progressive disease
(PD) within 8 weeks of randomization could be assessed
(patients with measurable disease who were evaluated at least
once after the baseline assessment), correlation studies were
performed to identify baseline characteristics that were cor-
related with early progression. Early PD was defined as any
patient who had disease progression before or at the end of
their second 4-week cycle of study medication (erlotinib or
placebo), or who died of NSCLC within that period. Similar
analyses were undertaken to define baseline characteristics
correlated with early death (defined as death within 3 months
of randomization) including all 727 patients. 2 tests were
TABLE 1. (Continued )
Factor
Number
Evaluable
Early PD Within
First 8 wk
Disease Control
(CR/PR/SD) p
EGFR FISH 0.042
High copy 24 7 (29.2%) 17 (70.8%)
Low copy 56 33 (58.9%) 23 (41.1%)
Unknown 318 171 (53.77%) 147 (46.2%)
Mutation status 0.599
Wild type 85 41 (48.2%) 44 (51.8%)
Mutation 21 11 (52.4%) 10 (47.6%)
Unknown 292 159 (54.5%) 133 (45.6%)
CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease; EGFR, epidermal growth factor
receptor; FISH, fluorescent in situ hybridization; LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group
performance status.
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used to assess the relationships between categorical variables.
Kaplan Meier20 curves were used to estimate the distributions
of time to event outcomes (progression free survival, and
overall survival). The Cox regression model20 was used to
establish the model for the Prognostic Index and the log-rank
test20 was used to test the difference between treatment arms.
RESULTS
Analysis of Early Progression
To find factors that potentially could characterize
groups of patients who might not benefit from erlotinib,
comparisons of baseline clinical and laboratory factors for
patients with early PD and those who had a clinical benefit
(complete response [CR], partial response [PR], or stable disease
[SD]) for at least 8 weeks are shown in Table 1. Significantly
more patients experienced early PD on the placebo arm com-
pared with those on erlotinib (p 0.0001). Other clinical factors
that correlated to early PD were PS 2 or 3 (p  0.007), PD as
best response to prior chemotherapy (p  0.006), weight loss
5% (p  0.0007) and non-Asian ethnicity (p  0.024), while
time from diagnosis to randomization 12 months was of
borderline significance (p  0.053).
Laboratory parameters associated with early PD in-
cluded baseline anemia (p  0.008), absence of EGFR
protein expression (p  0.006), and low EGFR gene copy
number (p  0.042). EGFR mutation status was not predic-
tive of early progression, although the number of patients in
this analysis was small.
Analysis of Early Death
Similarly, comparisons of baseline clinical and labora-
tory factors for patients who died within 3 months of ran-
domization and those who survived longer than 3 months are
shown in Table 2. Interestingly, treatment with placebo was
not associated with a higher risk of early death (29.7% for
placebo versus 28.0% for erlotinib, p  0.63). For treated
patients, clinical factors associated with early death included
PS 2 or 3 (p  0.0001), lack of response to prior chemother-
apy (p  0.0001), non-Asian ethnicity (p  0.01), time from
diagnosis to randomization 12 months (p  0.004) and
weight loss 5% (p  0.0001). The laboratory factors
significantly associated with early death were anemia (p 
0.0001) and elevated LDH (p  0.0005).
TABLE 2. Analysis of Survival at 3 mo
Factor No.
Survival
<3 mo
Survival
>3 mo
Unadjusted
p
Treatment 0.63
Erlotinib 485 136 (28.0%) 349 (72.0%)
Placebo 242 72 (29.7%) 170 (70.3%)
Age 0.88
60 yr 206 57 (27.7%) 149 (72.3%)
60 yr 279 79 (28.3%) 200 (71.7%)
Gender 0.27
Male 313 93 (29.7%) 220 (70.3%)
Female 172 43 (25.0%) 129 (75.0%)
Pathology 0.80
Adenocarcinoma 244 67 (27.5%) 177 (72.5%)
Squamous 143 43 (30.1%) 100 (69.9%)
Other 98 26 (26.5%) 72 (73.5%)
Performance status 0.0001
0, 1 318 57 (17.9%) 261 (82.1%)
2, 3 167 79 (47.3%) 88 (52.7%)
Response to prior
treatment
0.0001
PD 101 48 (47.5%) 53 (52.5%)
SD 188 44 (23.4%) 144 (76.6%)
CR/PR 196 44 (22.4%) 152 (77.6%)
Prior regimens 0.60
1 241 65 (27.0%) 176 (73.0%)
2, 3 244 71 (29.1%) 173 (70.9%)
Prior platinum 0.56
Yes 451 125 (27.7%) 326 (72.3%)
No 34 11 (32.3%) 23 (67.7%)
Smoking history 0.18
Current 240 70 (29.2%) 170 (70.8%)
Ever 68 23 (33.8%) 45 (66.2%)
Never 93 18 (19.4%) 75 (80.7%)
Unknown 84 25 (29.8%) 59 (70.2%)
Ethnicity 0.01
Oriental 62 9 (14.5%) 53 (85.5%)
Other 423 127 (30.0%) 296 (69.9%)
Time from diagnosis 0.004
12 mo 217 75 (34.6%) 142 (65.4%)
12 mo 268 61 (22.8%) 207 (77.2%)
Weight loss 0.0001
5% 319 67 (21.0%) 252 (79.0%)
5% 146 64 (43.8%) 82 (56.2%)
Unknown 20 5 (25.0%) 15 (75.0%)
LDH 0.0005
Normal 246 50 (20.3%) 196 (79.7%)
Increased 218 80 (36.7%) 138 (63.3%)
Unknown 21 6 (28.6%) 15 (71.4%)
Anemia 0.0001
Yes 338 118 (34.9%) 220 (65.1%)
No 147 18 (12.2%) 129 (87.8%)
EGFR protein
expression
0.38
Positive 106 25 (23.6%) 81 (76.4%)
Negative 139 44 (31.7%) 95 (68.4%)
Unknown 240 67 (27.9%) 173 (72.1%)
Factor No.
Survival
<3 mo
Survival
>3 mo
Unadjusted
p
EGFR FISH 0.52
High copy 28 6 (21.4%) 22 (78.4%)
Low copy 61 20 (32.8%) 41 (67.2%)
Unknown 396 110 (27.8%) 286 (72.2%)
Mutation status 0.71
Wild type 93 24 (25.8%) 69 (74.2%)
Mutation 22 5 (22.7%) 17 (77.3%)
Unknown 370 107 (28.9%) 263 (71.1%)
CR, complete response; PR, partial response; SD, stable disease; PD, progressive
disease; EGFR, epidermal growth factor receptor; FISH, fluorescent in situ hybridiza-
tion; LDH, lactate dehydrogenase; ECOG PS, Eastern Cooperative Oncology Group
performance status.
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Prognostic Index
This analysis was based on 727 treated patients in the
study (erlotinib and placebo). The Prognostic Index was
developed first using 485 treated patients in the erlotinib arm,
based on the primary end point of overall survival. Using the
Cox-regression model with stepwise selection procedures
based on the minimum AIC,18 10 prognostic factors (smoking
history, PS, weight loss, ethnicity, anemia, high LDH, best
response to prior chemotherapy [CR or PR, SD or PD], time
from diagnosis to randomization, number of prior regimens,
and EGFR gene copy number measured by Fluorescence In
Situ Hybridization) were found to be statistically significant
(Table 3), and these were assigned points that were based on
their level of significance (estimated coefficient in the prog-
nostic model, Table 4). These were then used to determinate
4 categories of risk as shown in Table 5: Low Risk (18
points), Intermediate Low Risk (18–23 points), Intermediate
High Risk (24–35 points), and High Risk (35 points),
according to the 10th, 50th, and 90th percentile of the index
score established in the treatment arm.
Figure 1 shows the overall survival of patients in the four
established risk categories derived from the Prognostic Index for
the erlotinib-treated patients (Figure 1A) and placebo patients
(Figure 1B). Figure 2A shows that the greatest survival benefit
from erlotinib was seen in patients in the Low Risk prognostic
TABLE 3. Coefficient Estimates From the Final Model in
Multivariate Cox regression Model
Factors and Levels Coefficient p
ECOG PS 2–3 0.4677 0.0001
Response to prior chemotherapy CR
or PR
0.0485 0.69
Response to prior chemotherapy PD 0.3295 0.022
Number of prior regimens 2 or 3 0.1947 0.071
Smoking history unknown 0.4881 0.056
Current smoker 0.5302 0.001
Former smoker 0.8219 0.001
FISH unknown 0.6195 0.019
FISH low copy 0.8549 0.004
Ethnicity other than Oriental 0.4258 0.016
Time from diagnosis to randomization
12 mo
0.2825 0.012
Weight loss unknown 0.0603 0.83
Weight loss 5% 0.4576 0.001
LDH unknown 0.1537 0.57
LDH increased 0.3055 0.008
Anemia 0.2618 0.038
ECOG PS, Eastern Cooperative Oncology Group performance status; CR, complete
response; PR, partial response; SD, stable disease; PD, progressive disease; FISH,
fluorescent in situ hybridization; LDH, lactic dehydrogenase; Anemia, women Hb120
g/L, men Hb 136 g/L.
TABLE 4. Weighting of Prognostic Factors for the Derivation of the Prognostic Index
0 2 Points 4 Points 6 Points 8 Points 10 Points
ECOG PS 0–1 2–3
Smoking history Never Current/unknown Former
Weight loss 5%/unknown 5%
Anemiaa None Yes
LDH Normal Unknown Increased
Time from diagnosis 12 mo 12 mo
Response to prior treatment CR or PR
or SD
PD
EGFR-FISH High copy Unknown-failed Low copy
Ethnicity Oriental Other
Prior regimens 1 2–3
a Anemia: women Hb 120 g/L, men Hb 136 g/L.
ECOG PS, Eastern Cooperative Oncology Group performance status; LDH, lactic dehydrogenase; CR, complete response; PR, partial response; SD, stable disease; PD,
progressive disease.
TABLE 5. Prognostic Index Interpretation
Risk Category Definition
No. of Patients (Events)
Median Survival in mo
(Confidence Intervala) Hazard Ratio
(Confidence
Intervala) pErlotinib Placebo Erlotinib Placebo
Low risk 18 points 53 (21) 20 (15) 20.6 (17.0–Inf) 8.9 (4.6–Inf) 0.30 (0.15–0.60) 0.001
Intermediate low risk 18–27 points 189 (138) 102 (84) 10.4 (8.0–11.1) 7.6 (5.8–9.3) 0.74 (0.56–0.97) 0.03
Intermediate high risk 28–38 points 198 (173) 92 (82) 4.1 (3.7–4.7) 3.9 (3.3–5.1) 0.92 (0.70–1.19) 0.52
High risk 38 points 45 (44) 28 (27) 1.9 (1.3–2.2) 2.3 (1.2–3.3) 1.11 (0.69–1.80) 0.67
a 95% confidence interval.
Inf, not reached.
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group (median survival erlotinib 20.6 [14.3–] months versus
placebo 8.9 [3.6 to 16.8] months; HR 0.34 [0.18 to 0.67]; p 
0.001). They represent approximately 10% (53  20/727) of
patients in the entire BR.21 study. The Intermediate Low Risk
(median survival erlotinib 10.4 [8.0 to 11.1] months versus
placebo 7.6 [5.8 to 9.8] months; HR 0.76 [0.58 to 1.00]; p 
0.05) had lesser survival benefits (Figure 2B) and Intermediate
High Risk (median survival erlotinib 4.0 [3.5 to 4.7] months
versus placebo 4.1[ 3.3 to 5.1] months; HR 0.92 [0.71 to 1.19];
p 0.51) had no apparent survival benefit (Figure 2C). Patients
in the High Risk group did not seem to benefit from erlotinib
therapy (median survival erlotinib 1.9 [1.3 to 2.2] months versus
placebo 2.3 [1.2 to 3.3] months; HR 1.07 [0.66 to 1.74], p 
0.78). This High Risk group also represented approximately
10% of patients (45 28/727) in the entire study. The trend test,
which assigned a score of 0, 1, 2, and 3 to the Low, Low
Intermediate, High Intermediate, and High Risk groups with its
interaction with treatment term included, showed that higher risk
was associated with shorter survival (p  0.001) and less
treatment effect (p  0.03).
FIGURE 1. Overall survival by
prognostic subgroup for erlotinib
and placebo patients. (A) Erlotinib,
and (B) Placebo.
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DISCUSSION
The art of selecting a medical therapy for any illness
lies not only in knowing which drugs to use to treat a specific
cancer, but also in the ability to select individual patients who
are most likely to benefit from the treatment. As a corollary
to this, it may be of equal importance to identify patients who
are not likely to respond or to live longer as a result of
therapy. This is particularly important for treatments that may
be associated with clinically relevant or severe toxicity, or for
which the cost benefit ratio of the treatment is likely to be
extremely high. While the formal health economic analyses
of BR.21 are in progress, the acquisition costs of drugs such
as erlotinib are approximately $3000.00 per month of treat-
ment. In the NCIC CTG BR.21 trial, the overall response rate
was only 9% for patients treated with erlotinib, yet a signif-
icant survival advantage was seen for treated patients com-
pared with those who received placebo.14 However, even in
the active treatment arm, 53% of patients experienced PD on
or before 8 weeks of treatment, and 28% of patients died
within 3 months of randomization. The observation that a
similar proportion of patients died within 3 months on both
the erlotinib and placebo arms suggested that a population of
patients on the active treatment arm of the study might not
have derived any benefit from therapy. We undertook this
analysis, therefore, in an attempt to identify potential patient
subgroups that may be unlikely to benefit from erlotinib or
other EGFR inhibitor therapy.
The prognostic factors that were found to be signifi-
cantly associated with survival in the treated subset of pa-
tients in BR.21 included many that have also been found to be
predictive of survival in response to first-line chemotherapy
in advanced NSCLC.6–10 These included PS, weight loss,
LDH level, and anemia. The association of a nonsmoking
history and Asian ethnicity have been reported to be prog-
nostic in many studies of EGFR inhibitor therapy22–28 and our
results were similar. These factors may be unique to this form
of treatment, as they have not been identified in any of the
cooperative group database analyses of chemotherapy stud-
ies; however, it is equally possible that these demographic
data had not been captured and for that reason were not
evaluated in the older chemotherapy studies.
Our model was able to define four patient groups within
the treated population that had distinct survival outcomes.
When the survival of patients in the Low Risk (longest
survival) treated group was compared with that of patients
with a similar Prognostic Index score in the placebo group, a
highly significant survival advantage was seen for erlotinib
(HR  0.34, p  0.001). In contrast, when treated patients
FIGURE 2. A comparison of sur-
vival by treatment group for the
four prognostic subgroups identi-
fied by the prognostic index
model. (A) Low Risk, (B) Intermedi-
ate Low Risk, (C) Intermediate High
Risk, and (D) High Risk.
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with the shortest survival (High Risk group) were compared
with patients with a similar Prognostic Index score in the
placebo group, no survival benefit from erlotinib was seen
(HR  1.07, p  0.78). This difference between the survival
of patients treated with erlotinib or placebo was not signifi-
cant, and although the HR is greater than one, it cannot be
concluded that these patients were harmed by erlotinib ther-
apy in view of the small number in the cohort and the
retrospective nature of these analyses. Thus, it seems that it
may be possible to identify from simple clinical and labora-
tory parameters, subgroups of patients who are likely to
derive clinically meaningful and statistically significant ben-
efit from erlotinib therapy and those who are unlikely to
benefit at all. However, each of these populations represented
only 10% of patients, in the trial.
The challenge of patient selection remains for the 80%
of patients who do not fall at the extremes of our Prognostic
Index model. Patients in our Intermediate Low Risk group
had longer survival than those in the Intermediate High Risk
group (median survivals of treated patients 10.4 and 4.0
months, respectively; untreated patients 7.6 and 4.1 month,
respectively). Although the relative benefit from erlotinib
therapy was of border-line significance in the Intermediate
Low risk group (HR  0.76, p  0.05), the 24% reduction in
the risk of death suggests that patients in this subgroup
deserve a trial of therapy. In contrast, with no apparent
survival benefit for patients in either the Intermediate High or
the High Risk groups, therapy is unlikely to be beneficial.
Prognostic Indexes have been derived for several
other cancers including multiple myeloma,29 non-Hodgkin
lymphoma,30,31 gestational trophoblastic tumors,32 and tes-
tis tumors.33 These indexes allow physicians to give pa-
tients an approximation of their prognosis at the initiation
of therapy. In addition, they have been used to stratify
patients within clinical trials or to develop specific trials
for patients with different expected survival outcomes.
Our Prognostic Index model based on clinical, patho-
logic, and laboratory characteristics requires prospective val-
idation to confirm that it is both prognostic and predictive of
outcome from treatment. If this is confirmed, it could be used
both to select patients for EGFR inhibitor therapy and to
stratify patients within clinical trials. In our model, assess-
ments of EGFR including EGFR protein expression, gene
copy number, and mutation status were not available for all
patients and did not add to the prognostic and predictive value
of clinical and laboratory parameters. However, if future
studies are able to include more patients with EGFR analysis
results, these may also be shown to be important.
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